MedTrace Logo

A Study of NH280105 in Healthy Adult Participants

NCT06870058 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-01-15

No results posted yet for this study

Summary

This is a Phase 1, randomized, double-blinded, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NH280105 in healthy volunteers. In addition, this study will evaluate the effects of food on NH280105 under a two-period study setting.

Conditions

  • Alzheimer Disease

Interventions

DRUG

NH280105- SAD

Dose formulation: Capsule Route of administration: oral

DRUG

NH280105- MAD

Dose formulation: Capsule Route of administration: oral

DRUG

Placebo

Matching placebo comparator

Sponsors & Collaborators

  • Jiangsu Nhwa Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Eric Sun · Head of Global BD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-12
Primary Completion
2025-11-13
Completion
2025-11-13

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06870058 on ClinicalTrials.gov